According to the poster, the study aimed to evaluate both the long-term effect of upadacitinib (Rinvoq, AbbVie) compared with adalimumab (Humira, AbbVie) through 56 weeks using RAPID3 scores in ...

New post-hoc analysis demonstrated efficacy of RINVOQ ® (upadacitinib) in moderate-to-severe atopic dermatitis patients with varying degrees of severity in head and neck involvement, with results ...

NORTH CHICAGO, Ill., Sept. 23, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present 27 abstracts across its dermatology portfo ...

New data presented at the European Association of Dermatology and Venereology (EADV) Congress 2023 delves into the outcomes of an ongoing phase 3 study, Measure Up 1 (NCT03569293), which assesses ...

Upadacitinib shows sustained efficacy and consistent safety for moderate to severe ulcerative colitis in long-term ... May 3-6, 2025; San Diego, CA. Poster 265. Newsletter. Stay ahead of ...

Treatment with 13 mg or 30 mg of upadacitinib showed improvement for patients with atopic dermatitis affecting the head and neck regions, according to a poster presented at the European Academy of ...

Upadacitinib may be more selective and reversible because it preferentially blocks JAK-1 or JAK1/3. In August 2019, ... In reviewing the poster presented at this meeting, ...

(RTTNews) - AbbVie (ABBV) announced Thursday that its Phase 2b study evaluating upadacitinib (RINVOQ) in adults with non-segmental vitiligo or NSV met the primary endpoint. Based on the data, the ...

Upadacitinib treatment resulted in a complete response in four patients (80%) within a median of 3.8 months and a partial response in one patient. CD remained dormant in the three patients with CD.